Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An initial U.S. clinical trial of SYN-2510/IMM2510 as a monotherapy or in combination with chemotherapy as a first-line in patients with non-small cell lung cancer

Next Previous
X
Search
Trial Profile

An initial U.S. clinical trial of SYN-2510/IMM2510 as a monotherapy or in combination with chemotherapy as a first-line in patients with non-small cell lung cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM-2510 (Primary) ; Antineoplastics
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Mar 2025 According to Instil Bio media release, the company anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC patients before the end of 2025, assuming the necessary regulatory approvals are obtained.
    • 04 Mar 2025 According to Instil Bio media release, the company Planned 100 patients in this trial
    • 04 Mar 2025 According to Instil Bio media release, the company announced that Clinical data for AXN-2510 (formerly SYN-2510) /IMM2510 anticipated in 1H 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top